" In calendar 2H21 and 1H22, we look forward to Phase 1 results for PD1-Vaxx (determination of optimal
biological dose as monotherapy and combination therapy, respectively). In calendar 1H22 and 1H23, we look
forward to Phase 2 data for HER-Vaxx (PFS and OS, respectively). Initial Phase 1 results for CHECKvacc and
VAXinia are expected in calendar 2H22, all of which should serve as meaningful investment catalysts."
Roth just rated IMU a buy, page-24
-
- There are more pages in this discussion • 106 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
0.002(3.85%) |
Mkt cap ! $396.8M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.4¢ | 5.2¢ | $332.9K | 6.302M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 539790 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 1243558 | 12 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |